NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
November 17 meeting will address Phase 2 study design and potential regulatory pathways
November 17 meeting will address Phase 2 study design and potential regulatory pathways
Cash redemption simplifies the capital structure with no common shares issued in the redemption
CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive
CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the
Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved
CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the
Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time
Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its
FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the
